Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Citizens
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Price: $86.39 +0.68%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Citizens analyst Jonathan Wolleben lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $137.00 (from $146.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Mirum's zilurgisertib shows positive results in younger FOP patients
- Churchill Downs (CHDN) PT Lowered to $131 at Stifel, Stays on Stifel Select List
- Insmed (INSM) PT Lowered to $195 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
